Literature DB >> 26751160

Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod.

Amy K Forrestel1, Badri G Modi1, Sarah Longworth2, Marissa B Wilck2, Robert G Micheletti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26751160     DOI： 10.1001/jamaneurol.2015.4259

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  13 in total

1.  Fungal immunology in clinical practice: Magical realism or practical reality?

Authors:  Christina C Chang; Stuart M Levitz
Journal:  Med Mycol       Date:  2019-06-01       Impact factor: 4.076

Review 2.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

Review 3.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

4.  Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod.

Authors:  Chengde Pham; Iwan Bennett; Rondhir Jithoo
Journal:  BMJ Case Rep       Date:  2017-07-06

Review 5.  Infectious Complications of Novel Multiple Sclerosis Therapies.

Authors:  S N Levin; T B Kaplan
Journal:  Curr Infect Dis Rep       Date:  2017-02       Impact factor: 3.725

6.  Cerebral Venous Thrombosis due to Cryptococcus in a Multiple Sclerosis Patient on Fingolimod.

Authors:  Joel A Kammeyer; Nicole M Lehmann
Journal:  Case Rep Neurol       Date:  2022-06-24

Review 7.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

8.  Case Report: Fingolimod and Cryptococcosis: Collision of Immunomodulation with Infectious Disease.

Authors:  Rohini D Samudralwar; Andrej Spec; Anne H Cross
Journal:  Int J MS Care       Date:  2019 Nov-Dec

9.  Disseminated Cryptococcosis in a 63-year-old Patient with Multiple Sclerosis Treated with Fingolimod.

Authors:  Hiroyuki Seto; Mitsushige Nishimura; Katsuhiro Minamiji; Sonoko Miyoshi; Hiroyuki Mori; Kenji Kanazawa; Hisafumi Yasuda
Journal:  Intern Med       Date:  2016-11-15       Impact factor: 1.271

Review 10.  Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis.

Authors:  Charlotte Druart; Souraya El Sankari; Vincent van Pesch
Journal:  Patient Relat Outcome Meas       Date:  2017-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.